Lilly Announces Acquisition of Sigilon Therapeutics

Published on: 

Deal comes amid collaboration on encapsulated cell therapies.

Eli Lilly and Company has announced an agreement to acquire Sigilon, a biopharmaceutical company. According to the company, the collaboration started in 2018 to develop encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes. Lilly states that their goal is to free patients from constant disease management by sensing blood glucose levels, restoring insulin production and releasing it over the long term.


"Despite significant advancement in treatment for people living with type 1 diabetes, many continue to live with a high disease burden every day," said Ruth Gimeno, Ph.D., group vice president, diabetes, obesity and cardiometabolic research at Lilly. "By combining Sigilon's talent and expertise in cell therapy with the knowledge and skills of Lilly's research and development teams, we will enhance opportunities to create innovative islet cell therapy solutions to improve the care of people living with diabetes."

Reference: Lilly to Acquire Sigilon Therapeutics. Lilly. June 29, 2023. Accessed June 30, 2023.